Antibiotics: Xerava receives FDA approval for the treatment of complicated intra-abdominal infections

Watertown, MA biopharmaceutical company, Tetraphase Pharmaceuticals, Inc. announced Monday that the US Food and Drug Administration (FDA) has granted approval of XERAVAa (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI). In clinical trials, XERAVA was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators - ertapenem and meropenem. ["]

The post Antibiotics: Xerava receives FDA approval for the treatment of complicated intra-abdominal infections appeared first on Outbreak News Today.